KOSP Kos Pharmaceuticals

Kos Pharmaceuticals, Inc. (Nasdaq:KOSP), a fully integrated specialty pharmaceutical company, will announce results for the second quarter ended June 30, 2006, before the market opens on Tuesday, August 8, 2006. Following the release, Kos' senior management will host a conference call at 8:30 a.m. ET to discuss the Company's results. The conference call will be available live via the Internet by accessing Kos' website at www.kospharm.com. Please go to the website at least fifteen minutes prior to the call to register, download and install any necessary audio software. Those who cannot access the webcast can dial into the conference call at 913-981-4911 confirmation code 6754547. A replay will also be available on the website at www.kospharm.com or by calling 888-203-1112 domestic or international, and entering 6754547 from 2:00 PM ET on August 8, 2006 until 12:00 AM ET on August 15, 2006. If you would like to receive notices and news regarding Kos, please visit the Investor Relations section of the Company website and subscribe to email alerts. Kos Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical company engaged in developing, commercializing, manufacturing and marketing proprietary prescription products for the treatment of chronic diseases with a particular focus on the cardiovascular, metabolic and respiratory disease areas. The Company's principal product development strategy is to reformulate existing pharmaceutical products with large market potential to improve safety, efficacy, and patient compliance. Kos' strategy also includes making measured investments in new chemical entity research through in-house and sponsored research, scientific in-licensing and general corporate development activities. The Company currently markets Niaspan(R), Advicor(R), Azmacort(R), Cardizem(R)LA, Teveten(R) and Teveten(R)HCT. Kos has a strong and growing research and development pipeline including proprietary drug delivery technologies in solid-dose, inhalation and aerosol metered-dose device administration to help fuel sustained, organic sales growth into the future. Certain statements in this press release, including statements relating to the Company's strong and growing research and development pipeline and future sales growth are forward-looking and are subject to risks and uncertainties which may cause actual results to differ materially from those projected in a forward-looking statement. These risks and uncertainties include the Company's ability to successfully develop and commercialize new products under development, the Company's ability to enter into new business development and corporate opportunities, the progress of the company's research and development pipeline, the protection afforded by the Company's patents, the effect of conditions in the pharmaceutical industry and the economy in general, and the Company's ability to maintain compliance with FDA. A more detailed discussion of risks attendant to the forward-looking statements included in this press release are set forth in the "Forward-Looking information: Certain Cautionary Statements" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2005, filed with the Securities and Exchange Commission, and in other reports filed with the SEC.